Marchini S - Search Results

1

Antitumour activity of trabectedin in myelodysplastic/myeloproliferative neoplasms.

Romano M, Della Porta MG, Gallì A, Panini N, Licandro SA, Bello E, Craparotta I, Rosti V, Bonetti E, Tancredi R, Rossi M, Mannarino L, Marchini S, Porcu L, Galmarini CM, Zambelli A, Zecca M, Locatelli F, Cazzola M, Biondi A, Rambaldi A, Allavena P, Erba E, D'Incalci M. Romano M, et al. Among authors: marchini s. Br J Cancer. 2017 Jan;116(3):335-343. doi: 10.1038/bjc.2016.424. Epub 2017 Jan 10. Br J Cancer. 2017. PMID: 28072764 Free PMC article.

2

Sequence-specific DNA interactions by novel alkylating anthracycline derivatives.

Marchini S, Gonzalez Paz O, Ripamonti M, Geroni C, Bargiotti A, Caruso M, Todeschi S, D'Incalci M, Broggini M. Marchini S, et al. Anticancer Drug Des. 1995 Dec;10(8):641-53. Anticancer Drug Des. 1995. PMID: 8595123

3

Sequence-specific DNA alkylation of novel tallimustine derivatives.

Marchini S, Cozzi P, Beria I, Geroni C, Capolongo L, D'Incalci M, Broggini M. Marchini S, et al. Anticancer Drug Des. 1998 Apr;13(3):193-205. Anticancer Drug Des. 1998. PMID: 9595033

4

Alpha-bromoacryloyl derivative of distamycin A (PNU 151807): a new non-covalent minor groove DNA binder with antineoplastic activity.

Marchini S, Cirò M, Gallinari F, Geroni C, Cozzi P, D'Incalci M, Broggini M. Marchini S, et al. Br J Cancer. 1999 Jun;80(7):991-7. doi: 10.1038/sj.bjc.6690453. Br J Cancer. 1999. PMID: 10362106 Free PMC article.

5

Mismatch repair deficiency is associated with resistance to DNA minor groove alkylating agents.

Colella G, Marchini S, D'Incalci M, Brown R, Broggini M. Colella G, et al. Among authors: marchini s. Br J Cancer. 1999 May;80(3-4):338-43. doi: 10.1038/sj.bjc.6690360. Br J Cancer. 1999. PMID: 10408835 Free PMC article.

6

Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743.

Minuzzo M, Marchini S, Broggini M, Faircloth G, D'Incalci M, Mantovani R. Minuzzo M, et al. Among authors: marchini s. Proc Natl Acad Sci U S A. 2000 Jun 6;97(12):6780-4. doi: 10.1073/pnas.97.12.6780. Proc Natl Acad Sci U S A. 2000. PMID: 10841573 Free PMC article.

7

Development of distamycin-related DNA binding anticancer drugs.

Marchini S, Broggini M, Sessa C, D'Incalci M. Marchini S, et al. Expert Opin Investig Drugs. 2001 Sep;10(9):1703-14. doi: 10.1517/13543784.10.9.1703. Expert Opin Investig Drugs. 2001. PMID: 11772279 Review.

8

Brostallicin, a novel anticancer agent whose activity is enhanced upon binding to glutathione.

Geroni C, Marchini S, Cozzi P, Galliera E, Ragg E, Colombo T, Battaglia R, Howard M, D'Incalci M, Broggini M. Geroni C, et al. Among authors: marchini s. Cancer Res. 2002 Apr 15;62(8):2332-6. Cancer Res. 2002. PMID: 11956092

9

Unique features of the mode of action of ET-743.

D'Incalci M, Erba E, Damia G, Galliera E, Carrassa L, Marchini S, Mantovani R, Tognon G, Fruscio R, Jimeno J, Faircloth GT. D'Incalci M, et al. Among authors: marchini s. Oncologist. 2002;7(3):210-6. doi: 10.1634/theoncologist.7-3-210. Oncologist. 2002. PMID: 12065793 Free article. Review.

10

Aplidine, a new anticancer agent of marine origin, inhibits vascular endothelial growth factor (VEGF) secretion and blocks VEGF-VEGFR-1 (flt-1) autocrine loop in human leukemia cells MOLT-4.

Broggini M, Marchini SV, Galliera E, Borsotti P, Taraboletti G, Erba E, Sironi M, Jimeno J, Faircloth GT, Giavazzi R, D'Incalci M. Broggini M, et al. Among authors: marchini sv. Leukemia. 2003 Jan;17(1):52-9. doi: 10.1038/sj.leu.2402788. Leukemia. 2003. PMID: 12529660

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

184 results

Search Page

Filters